US healthcare company Johnson & Johnson (NYSE: JNJ) on Friday announced the release of two-year Phase 3 results from ICONIC-TOTAL assessing ICOTYDE (icotrokinra) in adults and adolescents with moderate high-impact plaque psoriasis.
The oral peptide, which blocks the IL-23 receptor, was found to deliver sustained skin clearance through to Week 112.
Clear or almost clear skin (Investigator's Global Assessment 0/1) increased from 57% at Week 16 to 70% at Week 112 among treated patients. Site-specific complete clearance at Week 112 reached 60% in scalp psoriasis, 89% in genital psoriasis and 63% in psoriasis affecting the hands and/or feet.
Nail psoriasis also improved, with mean modified Nail Psoriasis Severity Index (mNAPSI) scores rising from 33% at Week 16 to 71% at Week 112. Safety findings remained consistent with the established profile, with no new signals reported.
ICONIC-TOTAL is part of a broader Phase 3 programme evaluating ICOTYDE across plaque psoriasis and related inflammatory conditions, including studies comparing the drug with placebo and deucravacitinib. ICOTYDE is approved in multiple regions for moderate-to-severe plaque psoriasis and is being studied in psoriatic arthritis, ulcerative colitis and Crohn's disease.
Bambusa Therapeutics prices upsized initial public offering
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
SciBase technology selected as primary endpoint in NIH-led skin exposure study
argenx reports positive Phase 2 results for FB102 in coeliac disease